Yohimbine hydrochloride inhibits benign prostatic hyperplasia by downregulating steroid 5α-reductase type 2

Yani Zhao,Yan Zhang,Yao Li,Min Yang,Jiani Yuan,Yu Cao,Lu Xu,Xuexinyu Ma,Sisong Lin,Junming An,Siwang Wang
DOI: https://doi.org/10.1016/j.ejphar.2021.174334
IF: 5.195
2021-10-01
European Journal of Pharmacology
Abstract:<p>Benign prostatic hyperplasia (BPH) is a frequently encountered disease in older men that affects sexual function and is capable of causing lower urinary tract dysfunction. Unfortunately, current treatment options for BPH primarily seek to address the lower urinary tract dysfunction aspect of the disease and do not improve sexual function. Yohimbine has been effectively used for decades to treat erectile dysfunction. Therefore, the objective of this study was to evaluate the inhibitory effect of yohimbine on BPH and explore the associated underlying mechanisms. Thirty-six rats were randomly divided into the control, BPH, finasteride (1 mg/kg), and yohimbine (2, 4, and 8 mg/kg) groups. Except for the rats in the control group, those in the other groups were subcutaneously injected testosterone propionate (5 mg/kg/day) daily for a period of 4 weeks to establish BPH models. They were also administration the corresponding drug daily for a period of 6 weeks. After the treatments, in addition to determining prostate wet weight and index, the histopathological status of the prostate was observed, and the levels of testosterone, dihydrotestosterone, prostatic acid phosphatase, the prostate-specific antigen, proliferating cell nuclear antigen, and steroid 5α-reductase were determined. Specifically, the administration of 2, 4, and 8 mg/kg yohimbine inhibited prostatic index increase by 46.7, 55.1, and 69.3%, respectively, in BHP rats. Further, yohimbine significantly reduced the levels of dihydrotestosterone, prostatic acid phosphatase, prostate-specific antigen, proliferating cell nuclear antigen, and steroid 5α-reductase, suggesting that it exerts beneficial effects against BPH by modulating the steroid 5α-reductase pathway.</p>
pharmacology & pharmacy
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the inhibitory effect of Yohimbine hydrochloride on Benign Prostatic Hyperplasia (BPH) and its underlying mechanisms. Specifically, the study aims to evaluate the effect of Yohimbine hydrochloride on inhibiting BPH by down - regulating Steroid 5α - reductase type 2 (SRD5A2). ### Background and problems 1. **The current situation of BPH**: - BPH is a common disease in elderly men, which affects sexual function and leads to lower urinary tract dysfunction. - Current treatment methods mainly focus on improving lower urinary tract symptoms, but fail to improve sexual function. 2. **Limitations of existing treatments**: - Commonly used drugs such as SRD5A inhibitors (e.g., finasteride) and α1 - adrenergic receptor antagonists (e.g., tamsulosin), although effective, have side effects such as erectile dysfunction and decreased libido. - Surgical treatment also has certain limitations and side effects. 3. **Mechanism of action of Yohimbine hydrochloride**: - Yohimbine hydrochloride is a natural indole alkaloid and is known to have a significant effect in the treatment of erectile dysfunction. - The study hypothesizes that Yohimbine hydrochloride may inhibit prostate hyperplasia by down - regulating SRD5A2 and reducing the level of Dihydrotestosterone (DHT). ### Research objectives - **Evaluate the inhibitory effect of Yohimbine hydrochloride on BPH**: Verify through animal experiments whether Yohimbine hydrochloride can effectively inhibit BPH. - **Explore its mechanism of action**: In particular, whether Yohimbine hydrochloride achieves the inhibition of BPH by down - regulating SRD5A2. ### Experimental design - Use a rat model to establish BPH, and administer different doses of Yohimbine hydrochloride (2 mg/kg, 4 mg/kg, 8 mg/kg) and the positive control drug finasteride (1 mg/kg) respectively. - Observe the changes in prostate wet weight, histopathological changes, and the levels of testosterone, DHT, Prostatic Acid Phosphatase (PAP), Prostate - Specific Antigen (PSA), Proliferating Cell Nuclear Antigen (PCNA) and SRD5A2 in serum and prostate tissue. ### Expected results - If Yohimbine hydrochloride can significantly reduce the prostate index, alleviate histopathological changes, and down - regulate the levels of DHT and SRD5A2, it indicates that it has potential therapeutic value for BPH. Through these studies, the author hopes to provide a new and more effective drug option for the treatment of BPH, especially for those patients who need to improve sexual function at the same time.